Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ - Henry Schein shares fall after appointing new Chief Financial Officer

BUZZ - Henry Schein shares fall after appointing new Chief Financial Officer

路透社路透社2026/10/08 11:47
Show original

October 8 - ** Shares of dental products distributor Henry Schein (HSIC.O) dropped 2% to $82 in pre-market trading. ** Ronald South, who has served as CFO for the past four years, will transition to Senior Advisor. ** Emmanuel Caprais will take over as CFO, officially assuming the role on November 4. ** Caprais was previously the Chief Financial Officer of global industrial manufacturer ITT. ** This leadership change comes about seven months after Frederick Lowery succeeded Stanley Bergman as CEO; Bergman had led the company for 35 years. ** Among 18 brokers, 9 rate the stock as “buy” or above, 8 as “hold”, and 1 as “sell”; the median target price is $96—data compiled by LSEG. ** As of the previous trading day's close, the stock has risen 10.69% year-to-date.

- ** Shares of dental product distributor Henry Schein (HSIC.O) fell 2% in pre-market trading to $82

** Ronald South, who has served as chief financial officer for the past four years, will move to the role of senior advisor

** Emmanuel Caprais will take over as chief financial officer, officially assuming the role on November 4

** Caprais previously served as chief financial officer of global industrial manufacturer ITT

** The personnel changes come about seven months after Frederick Lowery replaced Stanley Bergman as chief executive officer; Bergman had led the company for 35 years

** Of 18 brokerages, nine rate the stock as "buy" or higher, eight as "hold", and one as "sell"; the median price target is $96—data compiled by LSEG

** As of the close of the previous trading day, the stock is up 10.69% year to date


(To assist non-native English speakers, Reuters provides automated translation of its reports into several other languages. Because automated translation may contain errors or fail to provide needed context, Reuters does not guarantee the accuracy of automated translations and provides them solely for reader convenience. Reuters accepts no responsibility for any loss or damage resulting from use of this automated translation feature.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss